Endometrial Cancer : What Is New in Adjuvant and Molecularly Targeted Therapy?

Abstract EN

Endometrial cancer is the most common gynaecological cancer in western countries.

Radiotherapy remains the mainstay of postoperative management, but accumulating data show that adjuvant chemotherapy may display promising results after staging surgery.

The prognosis of patients with metastatic disease remains disappointing with only one-year survival.

Progestins represent an effective option, especially for those patients with low-grade estrogen and/or progesterone receptor positive disease.

Chemotherapy using the combination of paclitaxel, doxorubicin, and cisplatin is beneficial for patients with advanced or metastatic disease after staging surgery and potentially for patients with early-stage disease and high-risk factors.

Toxicity is a point in question; however, the combination of paclitaxel with carboplatin may diminish these concerns.

In women with multiple medical comorbidities, single-agent chemotherapy may be better tolerated with acceptable results.

Our increased knowledge of the molecular aspects of endometrial cancer biology has paved the way for clinical research to develop novel targeted antineoplastic agents (everolimus, temsirolimus, gefitinib, erlotinib, cetuximab, trastuzumab, bevacizumab, sorafenib) as more effective and less toxic options.

Continued investigation into the molecular pathways of endometrial cancer development and progression will increase our knowledge of this disease leading to the discovery of novel, superior agents.